Guide · Updated November 2026
GLP-1 Medicare Coverage in 2026: The $50/Month Program Explained
Since July 1, 2026, the Medicare GLP-1 Bridge has given eligible people with Part D coverage access to Foundayo, Wegovy, and the Zepbound KwikPen for weight management at a $50 monthly copayment. It is a temporary program that runs through December 31, 2027. It sits outside your regular Part D plan, so the $50 does not count toward your Part D out-of-pocket limit. Here is who qualifies, what it covers, and when your regular Part D plan applies instead.
Why Medicare did not cover weight-loss drugs before
Federal law excludes drugs used for weight loss from Part D coverage. That is why, before 2026, Part D plans could cover Wegovy or Zepbound only for other FDA-approved uses, such as:
- Wegovy to reduce the risk of major cardiovascular events in adults with established cardiovascular disease and obesity or overweight. That use is based on the SELECT trial, where semaglutide 2.4 mg cut major cardiovascular events by 20% versus placebo.
- Zepbound to treat moderate to severe obstructive sleep apnea in adults with obesity.
- Ozempic and Mounjaro for type 2 diabetes.
Those Part D routes still exist. CMS says people seeking GLP-1s for these uses should keep seeking coverage through their Part D plan.
How the Medicare GLP-1 Bridge works
CMS describes the Bridge as a short-term demonstration between July 1, 2026, and December 31, 2027. Key terms from Medicare and CMS:
- Covered drugs: Foundayo (tablet), Wegovy (injection or tablet), and the Zepbound KwikPen. Medicare says the program doesn’t cover single-dose Zepbound vials or pens.
- Cost: $50 for a one-month supply, regardless of income.
- Does not count toward Part D limits: The $50 doesn’t count toward your yearly Part D deductible or out-of-pocket limit.
- No Extra Help: Medicare says the copayment can’t be lowered by programs like Extra Help.
- No coupons: CMS tells pharmacies that coupons and discount programs may not be applied to Bridge claims.
- Prior authorization: Your provider sends the prescription and submits a prior authorization form when requested. Medicare says an approved prior authorization is valid through December 31, 2027, unless you change GLP-1s.
- Plans included: Standalone drug plans, Medicare Advantage plans with drug coverage, Special Needs Plans, employer group waiver plans, and LI NET.
Who qualifies for the Bridge
Medicare lists these requirements. You must be 18 or older and meet one of these when you start GLP-1 therapy:
| BMI | Plus at least one of |
|---|---|
| 35 or higher | No extra condition needed |
| 30 or higher | Heart failure with preserved ejection fraction, uncontrolled high blood pressure, or chronic kidney disease stage 3a or higher |
| 27 or higher | Prediabetes, a previous heart attack or stroke, or symptomatic peripheral artery disease |
You aren’t eligible if you:
- Already get GLP-1 drugs covered through your Part D plan.
- Have type 2 diabetes, moderate-to-severe sleep apnea, or fatty liver disease. Your Part D plan may cover your GLP-1 for those conditions instead.
A quick comparison: coverage routes by drug
| Drug | Medicare route | What you pay |
|---|---|---|
| Wegovy (injection or tablet) | Bridge for weight management, or Part D for other approved uses such as cardiovascular risk reduction | $50/month through the Bridge, or your Part D plan’s cost-sharing |
| Zepbound KwikPen | Bridge for weight management, or Part D for sleep apnea | $50/month through the Bridge, or your Part D plan’s cost-sharing |
| Zepbound vials and single-dose pens | Part D for sleep apnea only | Your Part D plan’s cost-sharing |
| Foundayo | Bridge for weight management | $50/month |
| Ozempic and Mounjaro | Part D for type 2 diabetes | Your Part D plan’s cost-sharing |
I am on Mounjaro personally. Because I have a T2D diagnosis, my coverage situation is different from someone using tirzepatide purely for obesity.
Compare GLP-1 providers
Browse Provider Directory →The Part D out-of-pocket cap
For drugs covered by your regular Part D plan, the 2026 standard benefit has a $615 deductible and a $2,100 annual out-of-pocket threshold. After you reach $2,100, you pay nothing more for covered Part D drugs for the rest of the year.
As an illustration, if your plan charged you $200 a month for a covered GLP-1 and you had no other drug costs, you would reach $2,100 in month 11. Remember that Bridge copayments do not count toward this cap.
Extra Help. Extra Help lowers Part D costs for people with limited income and resources. Medicare lists 2026 limits of $23,940 in income and $18,090 in resources for an individual. People with full Medicaid get it automatically. Extra Help does not lower the Bridge’s $50 copayment.
How to check your options
- Ask your doctor whether you meet the Bridge criteria, or whether your situation fits a Part D-covered use such as cardiovascular risk reduction, sleep apnea, or type 2 diabetes.
- Use Medicare’s eligibility questions on the Medicare weight loss drugs page, or call 1-800-MEDICARE.
- For Part D routes, check your plan’s formulary with the Medicare Plan Finder or by calling your plan.
If your Part D plan denies a drug, you, your representative, or your prescriber can ask for an appeal within 65 days from the date on the initial denial notice. The Bridge uses its own central prior authorization process.
What if you do not qualify
Manufacturer self-pay programs. As of Nov 4, 2026, NovoCare lists the Wegovy pill from $149 to $299 a month and the Wegovy pen at $349 a month. LillyDirect lists Zepbound from $299 a month for 2.5 mg, $399 for 5 mg, and $449 for 7.5 mg to 15 mg with refills within 45 days. Novo Nordisk says self-pay payments by government-insured patients do not count toward deductibles or out-of-pocket limits. Manufacturer copay cards cannot be used with Medicare.
Compounded drugs. Some telehealth companies sell compounded semaglutide or tirzepatide. Compounded drugs are not FDA approved. Read our compounded vs brand-name guide before you consider that route.
Switching plans. The Medicare Open Enrollment Period runs October 15 to December 7. If you rely on Part D coverage for a GLP-1, compare formularies before you switch.
For a full price breakdown, see our cheapest GLP-1 options guide and our guide to getting GLP-1 medications without insurance.
FAQ
Does Medicare cover Wegovy in 2026?
Yes, for eligible people. Through the Medicare GLP-1 Bridge, eligible Part D enrollees can get Wegovy for weight management for $50 a month through December 31, 2027. Part D plans can also cover Wegovy for cardiovascular risk reduction.
Does Medicare cover Zepbound for obesity?
Only the Zepbound KwikPen, through the Bridge, for eligible people. The Bridge does not cover Zepbound vials or single-dose pens. Part D plans can cover Zepbound for moderate to severe sleep apnea in adults with obesity.
Who qualifies for the $50/month GLP-1 copay under Medicare?
Part D enrollees 18 or older who meet BMI and health criteria when they start GLP-1 therapy: a BMI of 35 or higher, a BMI of 30 or higher with certain heart or kidney conditions or uncontrolled blood pressure, or a BMI of 27 or higher with prediabetes, a prior heart attack or stroke, or symptomatic peripheral artery disease. People with type 2 diabetes, moderate-to-severe sleep apnea, or fatty liver disease, or who already get a GLP-1 through Part D, are not eligible.
Can I use a manufacturer coupon for Wegovy or Zepbound if I am on Medicare?
No. Manufacturer copay cards exclude government insurance, and CMS says coupons cannot be applied to Bridge claims. You can still pay a manufacturer’s self-pay price outside Medicare, but it will not count toward your Part D limits.
What if my Medicare plan denies a GLP-1?
For a Part D denial, ask for an appeal within 65 days from the date on the denial notice. Ask your prescriber for a supporting statement. For the Bridge, follow the instructions in the notice from the central processor.
Bottom Line
The Medicare GLP-1 Bridge is the big change for 2026. Eligible Part D enrollees can get Foundayo, Wegovy, or the Zepbound KwikPen for weight management at $50 a month until December 31, 2027. People with type 2 diabetes, sleep apnea, fatty liver disease, or cardiovascular disease should look to their regular Part D plan instead. What happens after 2027 has not been settled, so watch for updates from CMS.
For help comparing providers if you need to go outside Medicare, see our GLP-1 provider directory.
Related
Guides:
- Cheapest GLP-1 Online · Insurance Coverage · Side Effects
- Mounjaro Dosage Guide · Oral vs Injectable · Exercise and Muscle
- GLP-1 Without Insurance · Fat Loss vs Weight Loss · Wegovy Pill vs Injection
Provider Reviews: Ro · Hims · MEDVi · Found · Calibrate
Compare: All Providers · Best GLP-1 Programs · All Guides
What we checked
This AI-assisted public-source desk check reviewed Medicare.gov pages on weight loss drugs, Extra Help, drug plan appeals, and enrollment periods, CMS pages and pharmacy guidance on the Medicare GLP-1 Bridge, the CMS 2026 Part D redesign fact sheet, the SELECT trial publication, the Zepbound label, and NovoCare and LillyDirect price pages on November 4, 2026. This is not a clinical review and it is not medical advice. Prices and policies change, so confirm them with the provider or your prescriber before you act.